Abstract
Fibrotic renal diseases represent a major health care problem because of their prevalence and the fact that available therapies merely slow, but do not halt progression to renal failure. New therapies to further slow or stop the progression to end stage of renal disease (ESRD) are urgently needed. PAI-1 has emerged as a powerful fibrogenic molecule in kidney disease and its overexpression has effects beyond its role in regulating the fibrinolytic system. PAI-1s ability to inhibit plasmin-dependent extracellular matrix turnover, to stimulate infiltration of macrophages and myofibroblasts and to signal directly to regulate transforming growth factor-beta 1 expression, provide possible mechanistic pathways involved in progression of chronic kidney disease. Blockade of PAI-1 represents a new and promising therapeutic approach that may help combat the current epidemic in chronic kidney disease.
Keywords: extracellular matrix (ECM), matrix metalloproteinases, Experimental Crescentic Glomerulonephritis, unilateral ureteral obstruction, transforming growth factor beta
Current Drug Targets
Title: PAI-1 as a Target in Kidney Disease
Volume: 8 Issue: 9
Author(s): Yufeng Huang and Nancy A. Noble
Affiliation:
Keywords: extracellular matrix (ECM), matrix metalloproteinases, Experimental Crescentic Glomerulonephritis, unilateral ureteral obstruction, transforming growth factor beta
Abstract: Fibrotic renal diseases represent a major health care problem because of their prevalence and the fact that available therapies merely slow, but do not halt progression to renal failure. New therapies to further slow or stop the progression to end stage of renal disease (ESRD) are urgently needed. PAI-1 has emerged as a powerful fibrogenic molecule in kidney disease and its overexpression has effects beyond its role in regulating the fibrinolytic system. PAI-1s ability to inhibit plasmin-dependent extracellular matrix turnover, to stimulate infiltration of macrophages and myofibroblasts and to signal directly to regulate transforming growth factor-beta 1 expression, provide possible mechanistic pathways involved in progression of chronic kidney disease. Blockade of PAI-1 represents a new and promising therapeutic approach that may help combat the current epidemic in chronic kidney disease.
Export Options
About this article
Cite this article as:
Huang Yufeng and Noble A. Nancy, PAI-1 as a Target in Kidney Disease, Current Drug Targets 2007; 8 (9) . https://dx.doi.org/10.2174/138945007781662373
DOI https://dx.doi.org/10.2174/138945007781662373 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
New drug therapy for eye diseases
Eyesight is one of the most critical senses, accounting for over 80% of our perceptions. Our quality of life might be significantly affected by eye disease, including glaucoma, diabetic retinopathy, dry eye, etc. Although the development of microinvasive ocular surgery reduces surgical complications and improves overall outcomes, medication therapy is ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Societal and Cultural Attitudes to Gout: An Important Consideration in the Successful Management of Gout among Maori in Aotearoa New Zealand
Current Rheumatology Reviews Subject index to volume 3
Current Molecular Medicine Evaluation of In Vivo Efficacy of Aqueous Extract of Aerial Parts of Cynodon dactylon in Rats with Simultaneous Type 2 Diabetes and Hypertension
Current Bioactive Compounds Lipid Lowering Therapy in the Elderly: Is there a Benefit?
Current Pharmaceutical Design Platelet Microparticles Induce Angiogenesis and Neurogenesis after Cerebral Ischemia
Current Neurovascular Research LINE-1 Methylation is Associated with an Increased Risk of Ischemic Stroke in Men
Current Neurovascular Research Structure, Production and Function of Erythropoietin: Implications for Therapeutical Use in Cardiovascular Disease
Current Medicinal Chemistry Inhibition of sPLA2-IIA, C-reactive Protein or Complement: New Therapy for Patients with Acute Myocardial Infarction?
Cardiovascular & Hematological Disorders-Drug Targets Oxidative Stress and the Pathogenesis of Atrial Fibrillation
Current Cardiology Reviews Therapeutic Strategy of Erythropoietin in Neurological Disorders
CNS & Neurological Disorders - Drug Targets Dietary Prevention of Coronary Heart Disease
Current Medicinal Chemistry - Immunology, Endocrine & Metabolic Agents Influence of Statin Use on Endothelial Function: From Bench to Clinics
Current Pharmaceutical Design Targeted Renal Delivery of Protein Kinase Inhibitors for the Treatment of Chronic Kidney Disease
Current Signal Transduction Therapy Anticancer Chemodiversity of Ranunculaceae Medicinal Plants: Molecular Mechanisms and Functions
Current Genomics Melatonin Leads to Axonal Regeneration, Reduction in Oxidative Stress, and Improved Functional Recovery Following Sciatic Nerve Injury
Current Neurovascular Research Diabetes Mellitus, Hypertension and Hypercholesterolemia in Relation to the 10-Year ACS Prognosis; the GREECS Study
Current Vascular Pharmacology Anti-inflammatory Treatment of Acute Coronary Syndromes
Current Pharmaceutical Design Role of Diagnostic Ultrasound in Patient Selection for Stroke Intervention
Recent Patents on CNS Drug Discovery (Discontinued) Nitroso-Redox Balance and Modulation of Basal Myocardial Function: An Update from the Italian Society of Cardiovascular Research (SIRC)
Current Drug Targets Is Erectile Dysfunction an Example of Abnormal Endothelial Function?
Current Vascular Pharmacology